Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles

Clinical Immunology

Volumn 121, Issue 1, 2006, Pages 54-62

  Godefroy, Emmanuelle ^a   Scotto, Luigi ^a   Souleimanian, Naira E ^a   Ritter, Gerd ^b   Old, Lloyd J ^a   Jotereau, Francine ^c   Valmori, Danila ^a   Ayyoub, Maha ^a  

^a Department of Medicine   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSERM   (France)

Author keywords

CD4+ T cells; Melan A; Melanoma; Tumor immunity; Vaccine

Indexed keywords

HLA DR ANTIGEN; HLA DR11 ANTIGEN; HLA DR52 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; UNCLASSIFIED DRUG;

ALLELE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; EPITOPE MAPPING; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NORMAL HUMAN; PRIORITY JOURNAL;

ALLELES; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CLONE CELLS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HLA-DR5 ANTIGEN; HUMANS; MELANOMA; NEOPLASM PROTEINS; PEPTIDE MAPPING;

EID: 33748685866     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.05.007     Document Type: Article

References (52)

1. Toes R.E., Ossendorp F., Offringa R., and Melief C.J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189 (1999) 753-756
2. Wang R.F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22 (2001) 269-276
3. Pieper R., Christian R.E., Gonzales M.I., Nishimura M.I., Gupta G., Settlage R.E., Shabanowitz J., Rosenberg S.A., Hunt D.F., and Topalian S.L. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J. Exp. Med. 189 (1999) 757-766
4. Wang R.F., Wang X., Atwood A.C., Topalian S.L., and Rosenberg S.A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284 (1999) 1351-1354
5. Wang R.F., Wang X., and Rosenberg S.A. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J. Exp. Med. 189 (1999) 1659-1668
6. Chaux P., Vantomme V., Stroobant V., Thielemans K., Corthals J., Luiten R., Eggermont A.M., Boon T., and van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med. 189 (1999) 767-778
7. Manici S., Sturniolo T., Imro M.A., Hammer J., Sinigaglia F., Noppen C., Spagnoli G., Mazzi B., Bellone M., Dellabona P., and Protti M.P. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189 (1999) 871-876
8. Jager E., Jager D., Karbach J., Chen Y.T., Ritter G., Nagata Y., Gnjatic S., Stockert E., Arand M., Old L.J., and Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191 (2000) 625-630
9. Zarour H.M., Storkus W.J., Brusic V., Williams E., and Kirkwood J.M. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 60 (2000) 4946-4952
10. Zeng G., Wang X., Robbins P.F., Rosenberg S.A., and Wang R.F. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3964-3969
11. Ayyoub M., Hesdorffer C.S., Metthez G., Stevanovic S., Ritter G., Chen Y.T., Old L.J., Speiser D., Cerottini J.C., and Valmori D. Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J. Immunol. 172 (2004) 7206-7211
12. Ayyoub M., Hesdorffer C.S., Montes M., Merlo A., Speiser D., Rimoldi D., Cerottini J.C., Ritter G., Scanlan M., Old L.J., and Valmori D. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J. Clin. Invest. 113 (2004) 1225-1233
13. Ayyoub M., Merlo A., Hesdorffer C.S., Rimoldi D., Speiser D., Cerottini J.C., Chen Y.T., Old L.J., Stevanovic S., and Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J. Immunol. 174 (2005) 5092-5099
14. Ayyoub M., Merlo A., Hesdorffer C.S., Speiser D., Rimoldi D., Cerottini J.C., Ritter G., Chen Y.T., Old L.J., Stevanovic S., and Valmori D. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin. Immunol. 114 (2005) 70-78
15. Topalian S.L., Gonzales M.I., Parkhurst M., Li Y.F., Southwood S., Sette A., Rosenberg S.A., and Robbins P.F. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183 (1996) 1965-1971
16. Kobayashi H., Kokubo T., Sato K., Kimura S., Asano K., Takahashi H., Iizuka H., Miyokawa N., and Katagiri M. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. 58 (1998) 296-301
17. Li K., Adibzadeh M., Halder T., Kalbacher H., Heinzel S., Muller C., Zeuthen J., and Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol. Immunother. 47 (1998) 32-38
18. Romero P., Valmori D., Pittet M.J., Zippelius A., Rimoldi D., Levy F., Dutoit V., Ayyoub M., Rubio-Godoy V., Michielin O., Guillaume P., Batard P., Luescher I.F., Lejeune F., Lienard D., Rufer N., Dietrich P.Y., Speiser D.E., and Cerottini J.C. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188 (2002) 81-96
19. Coulie P.G., Brichard V., Van Pel A., Wolfel T., Schneider J., Traversari C., Mattei S., De Plaen E., Lurquin C., Szikora J.P., et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180 (1994) 35-42
20. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Rivoltini L., Topalian S.L., Miki T., and Rosenberg S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3515-3519
21. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., Appella E., and Rosenberg S.A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180 (1994) 347-352
22. Marincola F.M., Shamamian P., Rivoltini L., Salgaller M., Cormier J., Restifo N.P., Simonis T.B., Venzon D., White D.E., and Parkinson D.R. HLA associations in the antitumor response against malignant melanoma. J. Immunother. Emphasis Tumor Immunol. 18 (1995) 242-252
23. Player M.A., Barracchini K.C., Simonis T.B., Rivoltini L., Arienti F., Castelli C., Mazzocchi A., Belli F., Parmiani G., and Marincola F.M. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother. Emphasis Tumor Immunol. 19 (1996) 357-363
24. Bettinotti M.P., Kim C.J., Lee K.H., Roden M., Cormier J.N., Panelli M., Parker K.K., and Marincola F.M. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J. Immunol. 161 (1998) 877-889
25. Schneider J., Brichard V., Boon T., Meyer zum Buschenfelde K.H., and Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int. J. Cancer 75 (1998) 451-458
26. Benlalam H., Linard B., Guilloux Y., Moreau-Aubry A., Derre L., Diez E., Dreno B., Jotereau F., and Labarriere N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J. Immunol. 171 (2003) 6283-6289
27. Zarour H.M., Kirkwood J.M., Kierstead L.S., Herr W., Brusic V., Slingluff Jr. C.L., Sidney J., Sette A., and Storkus W.J. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 400-405
28. Chen Y.T., Stockert E., Jungbluth A., Tsang S., Coplan K.A., Scanlan M.J., and Old L.J. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5915-5919
29. Valmori D., Souleimanian N.E., Hesdorffer C.S., Old L.J., and Ayyoub M. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals. Clin. Immunol. 117 (2005) 161-167
30. Valmori D., Fonteneau J.F., Lizana C.M., Gervois N., Lienard D., Rimoldi D., Jongeneel V., Jotereau F., Cerottini J.C., and Romero P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160 (1998) 1750-1758
31. The Data Book of the 11th International Histocompatibility Workshop: Yokohama vol. 2 (1991), Oxford University Press, New York, NY 807-814
32. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., and Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115 (2005) 739-746
33. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49 (1991) 281-355
34. Glennie M.J., and Johnson P.W. Clinical trials of antibody therapy. Immunol. Today 21 (2000) 403-410
35. Old L.J. Immunotherapy for cancer. Sci. Am. 275 (1996) 136-143
36. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 (1998) 2357-2368
37. James R.F., Edwards S., Hui K.M., Bassett P.D., and Grosveld F. The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology 72 (1991) 213-218
38. Ostrand-Rosenberg S., Thakur A., and Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144 (1990) 4068-4071
39. Verreck F.A., Termijtelen A., and Koning F. HLA-DR beta chain residue 86 controls DR alpha beta dimer stability. Eur. J. Immunol. 23 (1993) 1346-1350
40. Verreck F.A., van de Poel A., Drijfhout J.W., Amons R., Coligan J.E., and Konig F. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. Immunogenetics 43 (1996) 392-397
41. Sengar D.P., Goldstein R., Toye B., and Hampton N. Comprehensive typing of DR52 (DRB3)-associated DRB1 and DRB3 alleles by PCR-RFLP. Tissue Antigens 43 (1994) 286-294
42. Tang T.F., Huang A.Y., Pappas A., Slack R., Ng J., Hartzman R.J., and Hurley C.K. Relative frequencies of DRB1*11 alleles and their DRB3 associations in five major population groups in a United States bone marrow registry. Hum. Immunol. 61 (2000) 820-827
43. Texier C., Pouvelle-Moratille S., Busson M., Charron D., Menez A., and Maillere B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31 (2001) 1837-1846
44. Cotner T., Charbonneau H., Mellins E., and Pious D. mRNA abundance, rather than differences in subunit assembly, determine differential expression of HLA-DR beta 1 and -DR beta 3 molecules. J. Biol. Chem. 264 (1989) 11107-11111
45. Rudensky A., Preston-Hurlburt P., Hong S.C., Barlow A., and Janeway Jr. C.A. Sequence analysis of peptides bound to MHC class II molecules. Nature 353 (1991) 622-627
46. Chicz R.M., Urban R.G., Gorga J.C., Vignali D.A., Lane W.S., and Strominger J.L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178 (1993) 27-47
47. Lich J.D., Elliott J.F., and Blum J.S. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J. Exp. Med. 191 (2000) 1513-1524
48. Mukherjee P., Dani A., Bhatia S., Singh N., Rudensky A.Y., George A., Bal V., Mayor S., and Rath S. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis. J. Immunol. 167 (2001) 2632-2641
49. Dani A., Chaudhry A., Mukherjee P., Rajagopal D., Bhatia S., George A., Bal V., Rath S., and Mayor S. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment. J. Cell Sci. 117 (2004) 4219-4230
50. Vijayasaradhi S., Xu Y., Bouchard B., and Houghton A.N. Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J. Cell Biol. 130 (1995) 807-820
51. Diment S., Eidelman M., Rodriguez G.M., and Orlow S.J. Lysosomal hydrolases are present in melanosomes and are elevated in melanizing cells. J. Biol. Chem. 270 (1995) 4213-4215
52. Levy F., Muehlethaler K., Salvi S., Peitrequin A.L., Lindholm C.K., Cerottini J.C., and Rimoldi D. Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation. Mol. Biol. Cell 16 (2005) 1777-1787